Core Cap Advisors, LLC Arcutis Biotherapeutics, Inc. Transaction History
Core Cap Advisors, LLC
- $2.12 Billion
- Q4 2024
A detailed history of Core Cap Advisors, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 19 shares of ARQT stock, worth $242. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19Holding current value
$242% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
213Shares Held
130MCall Options Held
2.07MPut Options Held
151K-
Jennison Associates LLC12.3MShares$158 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$146 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$140 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$112 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$110 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $769M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...